Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
AssigneeRegulus Therapeutics Inc.
InventorsC. Frank Bennett, Susan M. Freier, Richard H. Griffey, Eric G. Marcusson
Life of this patent
Estimating the term…
Abstract
Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
Claims17
A method of treating or preventing a disease or disorder associated with a microRNA comprising:
- contacting an animal having or predisposed to the disorder with a therapeutically effective amount of compound comprising an oligomeric compound consisting of 15 to 30 monomeric subunits,
- wherein the oligomeric compound is at least 90% complementary to the microRNA, and at least one monomeric subunit is a modified nucleoside;
- and thereby treating or preventing the disease or disorder;
- wherein the disease or disorder is diabetes or hypertension, and the oligomeric compound reduces one or more markers of insulin response.
A method of modulating one or more phenotypic outcomes comprising:
- contacting a cell with a compound comprising an oligomeric compound consisting of 15 to 30 monomeric subunits,
- wherein the oligomeric compound is at least 90% complementary to a microRNA, and
- wherein at least one monomeric subunit is a modified nucleoside;
- and thereby modulating one or more phenotypic outcomes;
- wherein the one or more phenotypic outcomes is insulin response, and wherein the method further comprises detecting the modulation by a change in one or more markers of insulin response.
Dependencies are inferred from the claim text.